Benn P D, Mercey D E, Brink N, Scott G, Williams I G
Lancet. 2001 Mar 3;357(9257):687-8. doi: 10.1016/S0140-6736(00)04139-8.
Evidence suggests that nevirapine, a non-nucleoside reverse-transcriptase inhibitor, might be very effective in the prevention of HIV-1 integration and the reduction of risk of HIV-1 acquisition after exposure. We used a triple combination regimen, including nevirapine, for prophylaxis after occupational or sexual exposure to HIV-1 infection. Of 57 individuals who started therapy, only 41 returned for follow-up. Five had a grade three or four drug-induced hepatitis, two of whom also had a rash. This high rate of major adverse events raises concerns over the safety of such a regimen for its use in this population.
有证据表明，奈韦拉平（一种非核苷类逆转录酶抑制剂）在预防HIV-1整合以及降低暴露后感染HIV-1的风险方面可能非常有效。我们采用了包括奈韦拉平在内的三联组合疗法，用于职业或性接触HIV-1感染后的预防。在开始治疗的57人中，只有41人返回接受随访。5人发生了3级或4级药物性肝炎，其中2人还出现了皮疹。如此高的严重不良事件发生率引发了人们对该疗法在这一人群中使用安全性的担忧。
